Sponsor Dossier
Merck Healthcare
Sponsor Dossier for Merck Healthcare. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: BAVENCIO
- Brand: CETROTIDE
- Brand: CLADRITAB
- Brand: CRINONE
- Brand: ERBITUX
- Brand: GONAL-F
- Brand: LUVERIS
- Brand: MAVENCLAD
- Device (sponsor): Empty self-injector, electronic
- Device (sponsor): Needle, injector, medication/vaccine
- Device (sponsor): Injector, medication/vaccine, needle
About
Merck Healthcare is an Australian Private Company with ABN 72 006 900 830, registered in New South Wales. The entity is active and registered for GST from 1 July 2000.
Portfolio
Merck Healthcare holds 13 brands on the ARTG, with 13 indexable brands and 12 brands with Product Information on file. Ten brands have at least one PBS-listed item, 10 brands have PBAC outcomes on record, and 5 brands have AusPARs on record. Notable brands include BAVENCIO, CETROTIDE, CLADRITAB, CRINONE, ERBITUX, GONAL-F, LUVERIS, MAVENCLAD, OVIDREL, PERGOVERIS, REBIF, and SAIZEN.
Therapeutic focus —
Neurology: 3 brands — Oncology: 3 brands — Reproductive Health: 3 brands — Women's Health: 3 brands — Endocrinology: 1 brand
PBS footprint
Ten brands in the Merck Healthcare portfolio have at least one PBS-listed item, with the latest schedule date being 1 May 2026.
Regulatory activity
The most recent PBAC outcome for Merck Healthcare is dated 1 November 2024, with 10 brands holding PBAC outcomes on record. The latest AusPAR is dated 11 January 2022, with 5 brands holding AusPARs on record.